Alzheimer’s trials seeks tens of thousands of volunteers after landmark drug rejected
NICE has said the Alzheimer's disease drug is too expensive to be available on the NHS, but researchers are now hoping to ...
The Pharma Letter20h
Second Alzheimer’s drug, donanemab, rejected for NHS use
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved US pharma major Eli Lilly’s Kisunla (donanemab ...
Outsourcing-pharma20h
NICE rejects Donanemab for NHS use despite MHRA approval
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...
Second ‘game-changing’ Alzheimer’s drug donanemab gets green light in UK – but WON’T be available on NHS
A SECOND “game-changing” Alzheimer’s drug shown to slow the progression of the disease has been approved in the UK. Donanemab, developed by pharmaceutical giant Eli Lilly, was ...
Yahoo7h
Tens of thousands to be recruited into Alzheimer’s trials after landmark drug rejected
The National Institute for Health and Care Excellence (Nice) confirmed on Wednesday that it would not fund donanemab - the ...